<DOC>
	<DOCNO>NCT02757872</DOCNO>
	<brief_summary>The VITamin D OmegA-3 TriaL ( VITAL ; NCT 01169259 ) ongoing randomize clinical trial 25,875 US men woman investigate whether take dietary supplement vitamin D3 ( 2000 IU ) omega-3 fatty acid ( Omacor ( R ) fish oil , 1 gram ) reduce risk develop cancer , heart disease , stroke people prior history illness . The VITAL Kidney Function Hypertension ancillary study evaluate effect vitamin D omega-3 fatty acid kidney function among participant baseline hypertension .</brief_summary>
	<brief_title>Effects Vitamin D Fish Oil Kidney Hypertensives</brief_title>
	<detailed_description>This ancillary study VITamin D OmegA-3 TriaL ( VITAL ) test whether vitamin D3 , omega-3 fatty acid , prevent development progression kidney disease participant hypertension . Persons hypertension high risk kidney disease . Vitamin D omega-3 fatty acid promise intervention kidney disease prevention treatment , base result animal-experimental model early human study . Because intervention relatively safe , inexpensive , widely available , may offer opportunity substantially reduce burden kidney disease large population . This VITAL ancillary study test whether vitamin D3 and/or omega-3 fatty acid prevent loss glomerular filtration rate , 4 year therapy . In VITAL , 25,875 participant randomly assign 2x2 factorial design vitamin D3 ( cholecalciferol ) 2000 IU daily versus placebo , eicosapentaenoic acid 465 mg plus docosahexaenoic acid 375 mg daily versus placebo , follow mean 5 year assess effect cardiovascular disease cancer event . This ancillary study identify recruit sub-cohort VITAL participant hypertension baseline ascertain effect study intervention glomerular filtration rate group . Blood sample collect year 4 simultaneously measurement estimate glomerular filtration rate ( use serum creatinine cystatin C ) relevant biomarkers . This VITAL ancillary study design determine whether vitamin D3 and/or omega-3 fatty acid causal clinically relevant effect development progression kidney disease hypertensive .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Participants VITAL ( NCT 01169259 ) selfreported physician diagnosis hypertension eligible participate ancillary study Diagnosis diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Omega 3 fatty acid</keyword>
</DOC>